Interviews on biotechnology - Labiotech.eu

Generative AI in novel drug development

Sachin Rawat — Tue, 02 May 2023 08:15:22 +0000

Within months of its release, ChatGPT is finding use in almost all industries, including biotech, pharma, and healthcare. ChatGPT and other large language models like it belong to a family of artificial intelligence (AI) technologies dubbed generative AI. Based on statistical associations gathered from large datasets, generative AI models produce content similar to the data […]

The post Generative AI in novel drug development appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Phacilitate’s Women in Advanced Therapies program supports women in science

Jim Cornall — Wed, 08 Mar 2023 07:30:00 +0000

Marlin Frechette is the chief quality and compliance officer at FUJIFILM Irvine Scientific. But she has another role. Frechette is also a member of Phacilitate’s Women in Advanced Therapies program, and was formerly a mentor, and she tells us here how the program supports women in executive level life science roles. Frechette takes up the […]

The post Phacilitate’s Women in Advanced Therapies program supports women in science appeared first on Labiotech.eu.

How to ensure gender diversity in clinical trials

Jim Cornall — Wed, 08 Mar 2023 07:18:00 +0000

Labiotech sat down with Alicia Staley, VP, patient engagement at Medidata, a Dassault Systèmes company, to discuss underrepresentation of women in clinical trials and the importance of making trials more diverse. What does the current landscape look like with regards to gender diversity in clinical trials? While we’ve come a long way since the 1990s […]

The post How to ensure gender diversity in clinical trials appeared first on Labiotech.eu.

Interview: how has the first gene therapy for hemophilia B transformed research?

Roohi Mariam Peter — Fri, 03 Mar 2023 11:08:58 +0000

Hemophilia B, a rare disease that affects more than 230,000 people worldwide is caused by the lack of or defective clotting protein factor IX often due to a spontaneous mutation in the F9 gene, leading to excessive bleeding. Until recently, routine prophylactic infusions of factor IX replacement therapy to maintain enough clotting factor to prevent […]

The post Interview: how has the first gene therapy for hemophilia B transformed research? appeared first on Labiotech.eu.

The benefits – and challenges – of in-house CAR T-cell therapy

Jim Cornall — Fri, 17 Feb 2023 11:52:48 +0000

The Sheba Medical Center in Israel has an advanced hemato-oncology center that offers in-house CAR T-cell therapy, the revolutionary immunotherapy that alters a patient’s white blood cells to kill cancer cells. By keeping the entire process at the hospital, and not sending the cells to an external lab, the quality of the T-cells are better […]

The post The benefits – and challenges – of in-house CAR T-cell therapy appeared first on Labiotech.eu.

Foundation for the National Institutes of Health: partnering to tackle cancer

Jim Cornall — Wed, 01 Feb 2023 10:10:30 +0000

The Foundation for the National Institutes of Health (FNIH) takes on cancer through public-private research partnerships on prevention and early diagnosis. Dr Stacey Adam is associate vice president for research partnerships at the Foundation for the National Institutes of Health. In her role, she leads the cancer research partnership programs. Adam is a molecular pharmacologist/cancer […]

The post Foundation for the National Institutes of Health: partnering to tackle cancer appeared first on Labiotech.eu.

Scopio on the future of telehematology

Jim Cornall — Thu, 26 Jan 2023 10:40:09 +0000

Through full-field digital cell morphology, Scopio Labs’ technology can automate the analysis of tens of thousands of cells at a time. This could mean bringing earlier detection and diagnosis of cancers, infections, and other diseases, expediting patients’ access to better care and life-saving treatments. Erez Na’aman, co-founder and CTO of Scopio Labs, tells us about […]

The post Scopio on the future of telehematology appeared first on Labiotech.eu.

Watch: Queen’s University tackling antimicrobial resistance

Jim Cornall — Tue, 24 Jan 2023 08:28:00 +0000

One of the biggest global challenges facing healthcare systems is bacteria and viruses becoming resistant to drugs. Antimicrobial resistance (AMR) contributes to the deaths of around 700,000 people annually. Without new drugs or ways of dealing with AMR, the number of deaths could reach as many as 10 million per year by 2050 and cause […]

The post Watch: Queen’s University tackling antimicrobial resistance appeared first on Labiotech.eu.

Watch: pHion Therapeutics talks about next-generation mRNA vaccines

Jim Cornall — Mon, 23 Jan 2023 11:28:34 +0000

pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules, such as mRNA and DNA, in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based […]

The post Watch: pHion Therapeutics talks about next-generation mRNA vaccines appeared first on Labiotech.eu.

Interview: Proscia talks about digital pathology

Jim Cornall — Thu, 19 Jan 2023 09:56:21 +0000

Labiotech recently interviewed Nathan Buchbinder, chief product officer at Proscia, about digital pathology. AI has been a hot topic in drug discovery. Can you outline how it’s being applied to pathology data? Sure, it’s always great to start with such an exciting topic! There are two broad applications of AI that I want to highlight. […]

The post Interview: Proscia talks about digital pathology appeared first on Labiotech.eu.

Sibylla Biotech: how physicists met biologists to discover new drugs

Jonathan Smith — Wed, 14 Dec 2022 11:41:15 +0000

Discovering new drugs remains an inefficient, trial and error-based process. The founding team behind the Italian startup Sibylla Biotech explain how their interdisciplinary approach can speed up drug discovery in the protein degradation space. Protein degradation is a hot field in the biotech industry, with many pharmaceutical companies forging lucrative deals with protein degradation players. […]

The post Sibylla Biotech: how physicists met biologists to discover new drugs appeared first on Labiotech.eu.

Interview: why the recently approved fecal microbiome product is causing a rumble

Liza Laws — Mon, 05 Dec 2022 10:07:47 +0000

The news last week of the FDA approving Ferring Pharmaceuticals’ first fecal microbiome product, Rebyota, caused quite a stir in the field. The news was described as a huge step, a giant leap forward and simply fantastic. Paul Feurstadt is the director of non-inflammatory bowel disease research at the Medical Research Center of Connecticut. He also […]

The post Interview: why the recently approved fecal microbiome product is causing a rumble appeared first on Labiotech.eu.

LAG-3: The next big checkpoint inhibitor target

Jonathan Smith — Tue, 29 Nov 2022 17:44:17 +0000

Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The Australian-French firm Immutep explains why the immune checkpoint target LAG-3 is ripe for innovation in the space. Immune checkpoint inhibitors have revolutionized the field of immuno-oncology in the last decade, especially since the approval of […]

The post LAG-3: The next big checkpoint inhibitor target appeared first on Labiotech.eu.

Breaking barriers to gene therapies for childhood rare diseases

Jonathan Smith — Mon, 28 Nov 2022 16:03:57 +0000

The majority of known rare genetic diseases affect children, and gene therapies could help them live normal lives. Miquel Vila-Perelló, CEO and co-founder of the Spanish biotech SpliceBio, outlines how its technology could widen the range of genetic diseases treatable with gene therapies. Last week, World Children’s Day was celebrated as a means to improve […]

The post Breaking barriers to gene therapies for childhood rare diseases appeared first on Labiotech.eu.

What recent mixed clinical results can teach about Alzheimer’s disease

Jonathan Smith — Wed, 23 Nov 2022 17:02:50 +0000

2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon, explains the lessons these events provide. The quest for a treatment to slow the progression of Alzheimer’s disease has endured decades of disappointments. The most common treatment strategy — clearing up harmful deposits, or “plaques,” […]

The post What recent mixed clinical results can teach about Alzheimer’s disease appeared first on Labiotech.eu.

How cardioids can usher in the next generation of drug discovery

Omnia Ibrahim — Fri, 18 Nov 2022 11:40:23 +0000

The California-based Molecular Devices brings automated 3D cell culture and image analysis together with HeartBeat.bio’s cardioid technology to enable unique and scalable drug discovery and cardiac safety testing. Cardiovascular diseases are the leading cause of death worldwide, claiming an estimated 17.9 million lives each year. Despite this, the cardiovascular therapeutics market has lagged behind the […]

The post How cardioids can usher in the next generation of drug discovery appeared first on Labiotech.eu.

MaaT Pharma: leading the charge in microbiome therapeutics

Jonathan Smith — Mon, 14 Nov 2022 17:19:32 +0000

The first generation of microbiome therapeutics is hitting its first approvals. Savita Bernal, chief business officer at the French biotech MaaT Pharma outlines the firm’s efforts to blaze a trail in clinical testing and manufacturing in the new field. The microbiome world recently made a regulatory step forward as Australia greenlit a stool transplant developed […]

The post MaaT Pharma: leading the charge in microbiome therapeutics appeared first on Labiotech.eu.

In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus

Jim Cornall — Mon, 14 Nov 2022 10:56:12 +0000

AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the European Union (EU) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term […]

The post In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus appeared first on Labiotech.eu.

AI could tackle pharmaceutical manufacturing bottlenecks

Jonathan Smith — Mon, 07 Nov 2022 17:01:21 +0000

Artificial intelligence (AI) is making waves in the world of drug discovery. Rajiv Anand, founder and CEO of the firm Quartic.ai, explains how the tool could also make pharmaceutical manufacturing more efficient. The use of AI in drug discovery is attracting big investor interest; around $1.4 billion so far this year has gone to startups […]

The post AI could tackle pharmaceutical manufacturing bottlenecks appeared first on Labiotech.eu.

AI and biobanks could open the way to longevity treatments

Jonathan Smith — Mon, 31 Oct 2022 14:10:08 +0000

The development of longevity treatments is hampered by a lack of biomarkers and validated drug targets. BioAge’s co-founder and CEO, Kristen Fortney, explains how the firm is enlisting machine learning (ML), artificial intelligence (AI) and biobanks to fill in the gaps. The quest for human longevity treatments is attracting big cash in the biotech industry. […]

The post AI and biobanks could open the way to longevity treatments appeared first on Labiotech.eu.